News

Novartis reported sales of Fingolimod of $1,934m in 2013, representing a 62% increase from 2012. With the issuance of this patent, Mapi intends to develop a generic version

Patent #2007228341 covers the method and composition of matter for three-dimensional (3D) expansion of placental or adipose (fat) stromal cells, Pluristem’s key technology platform. Patent claims also include

Axxess president Daniel Bagi said: "This initial PO we believe is a sign of things to come, and we are very confident Mitch and his team at NPI

The study met its primary objective of protection from bleeds with fewer infusions. In the study, the site-specific PEGylated factor VIII provided protection from bleeds when used prophylactically

The Phase II trial met its primary safety endpoint and achieved statistically significant improvement in a measure of executive function (cognition), which included part of the trial’s main

The trial supplements the EINSTEIN Trial Programme, which established in the EINSTEIN Extension study that rivaroxaban 20mg once daily reduces the risk of long-term prevention of recurrent symptomatic

The deal covers the development and potentially the commercialization of Cellectis’ lead product candidate, UCART19, as well as the research, development, and commercialization of five other product candidates

With the acquisition, DKSH continues its strategic expansion in the industry by adding a direct presence in Macau to its pan-Asian coverage. With the move, DKSH is driving

Financial terms of the transaction are not disclosed. CoStim was founded in 2012 by MPM Capital managing director Luke Evnin together with MPM Capital operations managing director Robert